Long-term Effects Secondary to Cancer Therapy in Adults Clinical Trial
Official title:
Does Watercress Intake Have an Impact on Cancer Patients Outcomes: a Randomized Longitudinal Trial
Population studies associate a higher intake of cruciferous vegetables with a reduced risk
of cancer. Studies identified PEITC and several active isothiocyanates in watercress extract
that may have significant anticarcinogenic activity. Potential anticarcinogenic mechanisms
include: preventing carcinogen activation by inhibiting phase I enzymes such as cytochrome
P450s, by increasing cells' resistance through detoxification/antioxidant enzymes, by
inhibiting cell cycle progression and/or by inducing apoptosis.
These findings are justifiably interesting for the primary care setting and cancer primary
prevention. Yet, these cellular effects of watercress supplementation may further prove
useful in the modulation of cancer progression and disease recurrence. The present clinical
trial of nutritional supplementation in cancer, intends to further explore the effects of
therapeutic diets supplemented with nutraceuticals via watercress that may prove useful in
DNA damage modulation, as well as in the global disease prognosis.
The relation between cancer and nutrition has been well established; cancer builds upon
damage to cellular DNA resulting from carcinogenic environmental factors, in which nutrition
plays a major role. Many diet and lifestyle factors can influence the development of cancer,
a disease expected to affect worldwide more than 1 in 3 people. Population studies associate
a higher intake of cruciferous vegetables with a reduced risk of cancers at several
locations. In 1977, a study in laboratory animals showed the potential effect of phenylethyl
isothiocyanate (PEITC) to inhibit carcinogenesis. Recent studies identified several active
isothiocyanates in watercress extract that may have more significant anticarcinogenic
activity than PEITC alone. Potential anticarcinogenic mechanisms include: preventing
carcinogen activation by inhibiting phase I enzymes such as cytochrome P450s, by increasing
cells' resistance through detoxification/antioxidant enzymes; e.g. phase II enzymes (quinone
reductase, glutathione S-transferases, UDP glucuronosyltransferases);, by inhibiting cell
cycle progression and/or by inducing apoptosis.
Several watercress components have antigenotoxic effects in vitro resulting in reduced DNA
damage and have anti-proliferative effects. These components include flavonols such as
quercetin, hydroxycinnamic acids such as ferulic acid and p-coumaric acid. In HT29 colon
cancer cells, an extract of watercress juice was associated with inhibition of the three
stages of carcinogenesis: initiation, proliferation and metastasis. In MDA-MB-23 human
breast cancer cells, watercress extract inhibited metalloproteinase-9 activity, thus
suppressing the invasive potential of cancer cells. In breast cancer, epidemiological
studies suggest that cruciferous vegetables may reduce cancer incidence. In animal studies,
a 9-week PEITC-NAC supplemented diet vs a non-supplemented diet was significantly associated
with reduction in tumour size and weight.
A recognised mechanism by which PEITC inhibits the growth and survival of established cancer
cells is through the inhibition of angiogenesis. A study explored the impact of PEITC on a
specific pathway central to angiogenesis by exposing human MCF7 breast cancer cells to PEITC
and measuring hypoxia inducible factor (HIF) signaling activity. PEITC was shown as an
effective inhibitor of HIF activity which may contribute to its anti-angiogenic and
anti-cancer properties. A follow up to this experiment demonstrated that, similar to PEITC,
crude watercress extracts inhibited cancer cell growth and HIF activity in vitro.
Furthermore 6 to 8 hours after a significant amount dietary intake of watercress by four
healthy participants, peripheral blood cells demonstrated significantly reduced HIF
signalling activity, suggesting that dietary intake of watercress may be sufficient to
modulate this potential anti-cancer pathway.
Of further relevance, a blind, randomized crossover study was carried out in 60 healthy
volunteers instructed to consume one pack (85g) of raw watercress daily for 8 weeks.
Compared to the control phase, watercress supplementation increased lymphocytes' DNA
resistance to free radicals, thus reducing DNA damage. The hypothesis set out was that
watercress may reduce cancer risk via decreased damage to DNA and possible effects on
antioxidant status by increasing levels of plasma carotenoids.
These findings are justifiably interesting for the primary care setting and cancer primary
prevention. Yet, these cellular effects of watercress supplementation may further prove
useful in the modulation of cancer progression and disease recurrence, a not yet explored
area. Of note, that the role of nutrition intervention in medium and long term outcomes in
cancer has been demonstrated. It is today acknowledged as grade A evidence that
individualized nutritional counseling and education plays a central role in improving
long-term outcomes in cancer, by prolonging survival, reducing late RT toxicity and
improving QoL. The present clinical trial of nutritional supplementation in cancer, intends
to further explore the effects of therapeutic diets supplemented with nutraceuticals via
watercress that may prove useful in DNA damage modulation, as well as in the global disease
prognosis.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor)
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00956475 -
Quality of Life in Younger Leukemia and Lymphoma Survivors
|
Phase 1 | |
Active, not recruiting |
NCT01141231 -
Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer
|
Phase 3 | |
Completed |
NCT00410579 -
Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers
|
N/A | |
Completed |
NCT00755313 -
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
|
N/A | |
Completed |
NCT00662103 -
Aerobic Exercise, Resistance Exercise, or Flexibility and Relaxation Training in Inactive Older Female Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT04265638 -
Exercise Intervention in Adolescent and Young Adult Cancer Survivors
|
N/A | |
Completed |
NCT00415025 -
Side Effects of High-Dose Intensity-Modulated Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT00632983 -
Active Surveillance, Radical Prostatectomy, or Radiation Therapy in Treating Patients With Localized Prostate Cancer
|
Phase 3 | |
Terminated |
NCT00909662 -
Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers
|
N/A | |
Not yet recruiting |
NCT05322460 -
Web-based Intervention for Long-term Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT01087268 -
Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer
|
Phase 3 | |
Active, not recruiting |
NCT00400907 -
Observation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9
|
N/A | |
Completed |
NCT00599989 -
Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer
|
N/A | |
Withdrawn |
NCT00402935 -
Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer
|
N/A | |
Completed |
NCT00389584 -
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00799461 -
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
|
Phase 3 | |
Completed |
NCT00743236 -
Warm Ischemia or Cold Ischemia During Surgery in Treating Patients With Stage I Kidney Cancer
|
N/A | |
Terminated |
NCT03172988 -
Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery
|
Phase 4 | |
Completed |
NCT00410618 -
Neurological Effects of Chemotherapy and Radiation Therapy in Patients With Colon Cancer
|